文献速递前列腺癌

优化高危与局部区域前列腺癌的风险分层:随机试验的汇总分析

Refining Risk Stratification of High-risk and Locoregional Prostate Cancer: A Pooled Analysis of Randomized Trials.
PubMed 文献 · Eur Urol · 2024-05-22

该汇总分析纳入10项随机试验中3604例接受放疗联合长期雄激素剥夺治疗的高危/局部区域前列腺癌患者,评估Gleason评分≥8、cN1、cT3-4、PSA>20 ng/ml四个风险因素与结局的关系。结果显示cN1及2-3个风险因素者预后最差。

要点

  • Gleason评分≥8与无转移生存(MFS)HR=1.45、总生存(OS)HR=1.42相关。
  • cN1患者MFS HR=1.86、OS HR=1.77,10年MFS率36%、OS率47%。
  • 2-3个风险因素者10年MFS率53%、OS率60%,预后最差。

核心结论

  • 在放疗联合长期雄激素剥夺治疗下,cN0且具有2-3个风险因素或cN1的高危/局部区域前列腺癌患者结局最差。
  • 该分层有助于日常实践中的患者咨询及指导辅助试验。

研究设计与样本

  • 由Intermediate Clinical Endpoints in Cancer of the Prostate组汇总的10项随机对照试验的个体患者数据。
  • 纳入3604例高危/局部区域前列腺癌患者,定义为cN0背景下Gleason评分≥8、cT3-4、PSA>20 ng/ml任一风险因素或cN1疾病,均接受放疗联合长期雄激素剥夺治疗(18-36个月)。
  • 中位PSA值为24 ng/ml。

主要发现

  • Gleason评分≥8与较差结局相关:MFS HR=1.45,OS HR=1.42。
  • cN1疾病与较差结局相关:MFS HR=1.86,OS HR=1.77。
  • cT3-4疾病与较差结局相关:MFS HR=1.28,OS HR=1.22。
  • PSA>20 ng/ml与较差结局相关:MFS HR=1.30,OS HR=1.21。
  • 1个风险因素者调整后5年MFS率83%、10年MFS率63%、10年OS率67%;2-3个风险因素者分别为78%、53%、60%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Radiotherapy (RT) and long-term androgen deprivation therapy (ltADT; 18-36 mo) is a standard of care in the treatment of high-risk localized/locoregional prostate cancer (HRLPC). We evaluated the outcomes in patients treated with RT + ltADT to identify which patients have poorer prognosis with standard therapy. METHODS: Individual patient data from patients with HRLPC (as defined by any of the following three risk factors [RFs] in the context of cN0 disease-Gleason score ≥8, cT3-4, and prostate-specific antigen [PSA] >20 ng/ml, or cN1 disease) treated with RT and ltADT in randomized controlled trials collated by the Intermediate Clinical Endpoints in Cancer of the Prostate group. The outcome measures of interest were metastasis-free survival (MFS), overall survival (OS), time to metastasis, and prostate cancer-specific mortality. Multivariable Cox and Fine-Gray regression estimated hazard ratios (HRs) for the three RFs and cN1 disease. KEY FINDINGS AND LIMITATIONS: A total of 3604 patients from ten trials were evaluated, with a median PSA value of 24 ng/ml. Gleason score ≥8 (MFS HR = 1.45; OS HR = 1.42), cN1 disease (MFS HR = 1.86; OS HR = 1.77), cT3-4 disease (MFS HR = 1.28; OS HR = 1.22), and PSA >20 ng/ml (MFS HR = 1.30; OS HR = 1.21) were associated with poorer outcomes. Adjusted 5-yr MFS rates were 83% and 78%, and 10-yr MFS rates were 63% and 53% for patients with one and two to three RFs, respectively; corresponding 10-yr adjusted OS rates were 67% and 60%, respectively. In cN1 patients, adjusted 5- and 10-yr MFS rates were 67% and 36%, respectively, and 10-yr OS was 47%. CONCLUSIONS AND CLINICAL IMPLICATIONS: HRLPC patients with two to three RFs (and cN0) or cN1 disease had the poorest outcomes on RT and ltADT. This will help in counseling patients treated in routine practice and in guiding adjuvant trials in HRLPC. PATIENT SUMMARY: Radiotherapy and long-term hormone therapy are standard treatments for high-risk and locoregional prostate cancer. In this report, we defined prognostic groups within high-risk/locoregional prostate cancer and showed that outcomes to standard therapy are poorest in those with two or more "high-risk" factors or evidence of lymph node involvement. Such patients may therefore be the best candidates for intensification of treatment.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Ravi P, Xie W, Buyse M, et al. Refining Risk Stratification of High-risk and Locoregional Prostate Cancer: A Pooled Analysis of Randomized Trials. Eur Urol. 2024. PMID: 38777647. doi:10.1016/j.eururo.2024.04.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。